Skip to main content


Fig. 3 | Virology Journal

Fig. 3

From: Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach

Fig. 3

Protection of against vaginal challenge with HPV after vaccination with L2-recombinant adenoviruses either with or without adjuvant. Legend: Balb/c mice (5/group) were vaccinated s.c. three times at 3 week intervals with 1010 L2- or HA-recombinant adenovirus particles either in the absence (a,c) or presence (b,d) of adjuvant (50 μg aluminum hydroxide gel and 5 μg monophosphoryl lipid A), or controls Gardasil (0.1x human dose) or phosphate-buffered saline (PBS). Mice were challenged intravaginally with either HPV16 (a,b) or HPV56 (c,d) pseudovirions at 4 weeks after the final immunization. Three days later the infection was assessed by imaging of bioluminescence (RLU). The background bioluminescence of unchallenged mice (BK) is shown. **p < 0.01, *p < 0.05

Back to article page